Telix Pharmaceuticals (ASX:TLX) enters into an asset purchase agreement with antibody engineering company ImaginAb.

Following closing of its transaction with Telix Pharmaceuticals, ImaginAb, Inc. will be focused on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials ...

Telix Pharmaceuticals Limited has entered into an asset purchase agreement with antibody engineering company ImaginAb Inc. to ...

Lyell is focused on advancing next-generation CAR T cell therapies with the potential to deliver higher response rates and longer duration of responses for patients with hematologic malignancies and ...

The West African Gas Pipeline Company agreed to postpone its planned pipeline maintenance by two weeks, averting an imminent ...

09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today ...